An insight about online trading on NASDAQ: AB

An insight about online trading on NASDAQ: AB

Medicine is an important industry. It may not add too much to the economy but is necessary for mankind. In recent times, we have seen an increase in the number of people being diagnosed with diseases because of maintaining a poor lifestyle. Treatments that target the symptoms are not enough to cure the problem. 

Scientists are now trying to develop therapies that are genetically targeted, to fight the disease from the root. This approach towards medicine is the field of biotechnology. But sometimes, health problems cannot be treated with just medication, they also need external support to regulate the functions of the body. Devices that can be either fit inside the body or used from outside have proven to be life-saving. 

Investing in such companies is important and can give you steady returns. While there is a fair amount of risk in these stocks because it depends on the successful trial of the product. Investing in such companies gives them much-needed funding to run operations and come up with better products that can be life-saving for consumers and profitable for investors. 

A company operating in this industry is ABIOMED Inc. It was founded in 1981 and is headquartered in Danvers, Massachusetts. This company is engaged in research, development and sale of medical devices that assist or replace the pumping function of a failing heart. It also provides continuous care to heart failure patients. 

The company offers products like Impella 2.5 catheter which is a micro heart pump with integrated motor and sensors for interventional cardiology. Another product called Impella CP, a device used by cardiologists to support patients in the heart surgery suites, is also produced by the company. ABIOMED specialises in micro heart pumps and other devices that support heart function.   

ABIOMED Inc.’s shares are listed on the Nasdaq exchange. It goes by the ticker NASDAQ: ABMD at The stock has received an overall analyst rating of ‘hold’, with 4 ‘hold’, 4 ‘buy’ and 1 ‘Sell’ rating. Analysts are anticipating a downside in price target, from the current price of $298.52 to $193. ABIOMED Inc. has a market cap of $13.41 billion. Before the pandemic, the nasdaq abmd stock was traded at $151.13. In the ongoing pandemic situation, the stock is being traded for $297.76, registering a 97% increase in prices.    

The company reported EPS of $0.70 and earnings of $206.66 million in the first quarter of 2020. Key competitors of ABIOMED are Abbott Laboratories, Medtronic, Intuitive Surgical, Stryker, ResMed, Baxter International, IDEXX Laboratories, Boston Scientific, etc.  You can check more stock information at trading websites. Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Criss Roman